Analyst Gil Blum of Needham maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report), retaining the price target of $6.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Gil Blum has given his Buy rating due to a combination of factors surrounding Taysha Gene Therapies’ promising advancements in their TSHA-102 treatment for Rett syndrome. The company is expected to provide further insights at the upcoming IRSF meeting, which will include updated clinical data and comparisons with competitors, highlighting the potential efficacy of their treatment.
Additionally, the pivotal study design for TSHA-102, which is aligned with FDA guidelines, suggests a strong likelihood of success. The discussion will also address the commercial prospects and payor coverage for the therapy, as well as the safety profile of AAV-based gene therapies, all of which contribute to the positive outlook for Taysha’s stock.
According to TipRanks, Blum is an analyst with an average return of -12.7% and a 33.33% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Autolus Therapeutics, and Artiva Biotherapeutics, Inc..
In another report released on May 29, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $7.00 price target.